Table I.
Clinicopathological features of 259 patients with breast cancer, and the association with the expression of POSTN.
| POSTN expression, n | ||||
|---|---|---|---|---|
| Clinicopathological feature | n (%) | Negative | Positive | P-value |
| Total | 259 | 168 | 91 | |
| Age (years) | 0.248 | |||
| ≤50 | 115 (44.4) | 79 | 36 | |
| >50 | 144 (55.6) | 89 | 55 | |
| Tumor size | 0.123 | |||
| T1 | 142 (54.8) | 98 | 44 | |
| T2 | 117 (45.2) | 70 | 47 | |
| Histological grade | 0.001a | |||
| I | 29 (11.2) | 26 | 3 | |
| II | 160 (61.8) | 106 | 54 | |
| III | 70 (27.0) | 36 | 34 | |
| Nodal status | 0.023a | |||
| Negative | 146 (56.4) | 99 | 47 | |
| Positive | 113 (43.6) | 61 | 52 | |
| Molecular subtype | <0.001a | |||
| Luminal A | 71 (27.4) | 59 | 12 | |
| Luminal B | 84 (32.4) | 55 | 29 | |
| HER2-overexpressed | 34 (13.1) | 22 | 12 | |
| Triple-negative | 65 (25.1) | 28 | 37 | |
| Unclassified | 5 (1.9) | 4 | 1 | |
| Estrogen receptor status | <0.001a | |||
| Negative | 106 (40.9) | 54 | 52 | |
| Positive | 153 (59.1) | 114 | 39 | |
| Progesterone receptor status | <0.001a | |||
| Negative | 124 (47.9) | 67 | 57 | |
| Positive | 135 (52.1) | 101 | 34 | |
| HER2 status | 0.897 | |||
| Negative | 178 (68.7) | 115 | 63 | |
| Positive | 81 (31.3) | 53 | 28 | |
| Ki-67 expression | 0.011a | |||
| Low | 104 (40.2) | 77 | 27 | |
| High | 155 (59.8) | 91 | 64 | |
| Local recurrence | 0.034a | |||
| No | 242 (93.4) | 161 | 81 | |
| Yes | 17 (6.6) | 7 | 10 | |
| Postoperative distant metastasis | 0.002a | |||
| Negative | 227 (87.6) | 155 | 72 | |
| Positive | 32 (12.4) | 13 | 19 | |
| Survival status | 0.001a | |||
| Alive | 230 (88.8) | 157 | 73 | |
| Deceased | 29 (11.2) | 11 | 18 | |
a
P<0.05. POSTN, periostin; HER2, ErbB2 receptor tyrosine kinase 2.